Vestnik oftalmologii · 2025
[Monocyte telomere length as a novel biomarker of macular atrophy and response to anti-VEGF therapy in age-related macular degeneration].
Аннотация на английскомСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yusef Yu, Avetisov K S, Khalatyan A S, Shishparenok A N, Blinova V G, Gladilina Yu A, Zhdanov D D
Аннотация
UNLABELLED: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the elderly. Monocyte telomere length is proposed as a marker of cellular senescence in this condition.
PURPOSE: This study investigated the association between monocyte telomere length and retinal parameters in different forms of AMD, as well as in patients receiving antiangiogenic therapy.
MATERIAL AND METHODS: Monocyte telomere length was measured in 84 patients (mean age 79±9 years) divided into four groups: non-exudative AMD with geographic atrophy (neAMD-GA), neovascular AMD (nAMD) with macular atrophy (nAMD-MA), nAMD without MA, and controls. Monocytes were isolated using immunomagnetic separation, and telomere length was determined by quantitative PCR (qPCR). Retinal parameters were assessed via optical coherence tomography (OCT) of the macular region.
RESULTS: Significant telomere shortening was observed in AMD compared to the controls (p<0.05). In the nAMD-MA group, telomere length correlated positively with best-corrected visual acuity (BCVA) after treatment (rs=0.661; p=0.0014) and the type of atrophy (p<0.0001); shorter telomeres were associated with greater BCVA decline after therapy (rs=-0.452; p=0.0419). In nAMD without MA, telomere length correlated with reduced height of neuroepithelial detachment (NED) under anti-VEGF treatment (rs=0.50; p=0.0252). No significant associations were found in the neAMD-GA and control groups.
CONCLUSION: These findings highlight monocyte telomere length as a potential biomarker for predicting macular atrophy progression and treatment outcomes in AMD. Further research is needed to confirm these associations and to explore sex/ethnic disparities in telomere length in this disease.
PURPOSE: This study investigated the association between monocyte telomere length and retinal parameters in different forms of AMD, as well as in patients receiving antiangiogenic therapy.
MATERIAL AND METHODS: Monocyte telomere length was measured in 84 patients (mean age 79±9 years) divided into four groups: non-exudative AMD with geographic atrophy (neAMD-GA), neovascular AMD (nAMD) with macular atrophy (nAMD-MA), nAMD without MA, and controls. Monocytes were isolated using immunomagnetic separation, and telomere length was determined by quantitative PCR (qPCR). Retinal parameters were assessed via optical coherence tomography (OCT) of the macular region.
RESULTS: Significant telomere shortening was observed in AMD compared to the controls (p<0.05). In the nAMD-MA group, telomere length correlated positively with best-corrected visual acuity (BCVA) after treatment (rs=0.661; p=0.0014) and the type of atrophy (p<0.0001); shorter telomeres were associated with greater BCVA decline after therapy (rs=-0.452; p=0.0419). In nAMD without MA, telomere length correlated with reduced height of neuroepithelial detachment (NED) under anti-VEGF treatment (rs=0.50; p=0.0252). No significant associations were found in the neAMD-GA and control groups.
CONCLUSION: These findings highlight monocyte telomere length as a potential biomarker for predicting macular atrophy progression and treatment outcomes in AMD. Further research is needed to confirm these associations and to explore sex/ethnic disparities in telomere length in this disease.